Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced the commercial launch of ChrgD+, the industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format and empowered with DehydraTECH(TM) for fast, effective delivery. ChrgD+ is available online, now for sale to US consumers at ChrgD.life. Lexaria’s technology … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Commercial Launch of ChrgD+”
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a biotechnology company and drug-delivery platform innovator, is increasing the reach of its revolutionary DehydraTECH(TM) technology that enables the rapid onset of ingested cannabis. An article discussing the company reads, “DehydraTECH is a drug-delivery technology that gets ingested active pharmaceutical ingredient (API) molecules to the bloodstream faster than other … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Joint Manufacturing Partnership Opens Door to Widespread Distribution”
Lexaria recently announced its entry into a partnership with a tobacco giant to fund the research and development of oral nicotine delivery solutions The company received a cannabis R&D license from Health Canada LXRP also announced its receipt of four new patents and its launch of ChrgD+ Many consumers don’t realize that they don’t need … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Drug-Delivery Platform Could Help Smokers Stub Cigarettes”
Lexaria Bioscience is involved in the research and improvement of its trademarked DehydraTECH technology, which enhances the bioavailability of some legal drug substances used by consumers The technology provides a rapid-on, rapid-off effect that may be effectively used in cannabis-infused edibles and beverages as an alternative to mind-altering substances such as alcohol and cannabis New … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) R&D Finds Lack of Adverse Chemical Byproducts in Manufacture of Drug Delivery Compositions”
Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced the granting of four of its pending patent applications via its wholly-owned subsidiary Poviva Corp. According to the update, the new patents cover delivery of cannabinoids such as THC and CBD, NSAIDs such as ibuprofen, nicotine, and vitamins. With … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Receives Four New Patents, Increasing Total Granted to 15”
Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced the appointment of Brian Quigley to its board of directors. Quigley most recently spent 16 years at Altria Group, seven of which were spent as president and CEO for U.S. Smokeless Tobacco and Nu-Mark, Altria’s innovation company, during the … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Appoints Consumer Packaged Goods Veteran to Board of Directors”
Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) today announced that Health Canada has issued cannabis Research and Development (“R&D”) license LIC-7NONT76UNW-2019 to its subsidiary, Lexaria CanPharm ULC. According to the update, the license, which carries a four-year term unless renewed, is effective immediately and will allow one of … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) Subsidiary Receives Health Canada Cannabis R&D License”
Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced successful completion of its Master Collaborative Research Agreement (“the R&D Program”) with the National Research Council of Canada (“NRC”). The R&D program sought to investigate technical aspects and new opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions using … Continue reading “NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Completes Initial R&D Program with the National Research Council of Canada”
Lexaria’s patented DehydraTECH technology improves taste, achieves higher absorption rates and promotes fast onset of bioactive compounds, including nicotine and cannabinoids Nine corporate licensees have signed a total of 11 definitive contracts to use DehydraTECH technology in innovative beverages, edibles and oral products Lexaria expects to experience unprecedented revenue growth as many of its clients plan … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reviews Expansion of Client Base, Noting Unprecedented Number of License Agreements”
Lexaria Bioscience’s revolutionary DehydraTECH technology enables cannabis consumers to experience rapid-on, rapid-off effects in non-smoked formulations A just-announced joint manufacturing partnership between Lexaria and alcohol-free beverage maker Hill Street Beverage Company is paving the way for wider distribution of Lexaria’s platform Hill Street is the only company to have gained licenses to use DehydraTECH on … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Paves Way for New Cannabis Brand, B2B Sales through Partnership with Alcohol-Free Beverage Maker”
